FIGURE 3.
Characteristic response pattern with transient lymphocytosis typically peaking within the first 2 months of treatment, followed by gradual resolution over the next 6–8 months. Decrease in lymphadenopathy was consistent from the beginning. Data derived from relapsed/refractory CLL patients treated with single-agent ibrutinib (PCYC-1102 trial) (From data presented at American Society of Hematology Annual Meeting, San Diego, California, December, 2011).